

FORM-PTO-1390  
(Rev. 12-29-99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

001560-390

U.S. APPLICATION NO. (If known, see 37 CFR 1.51)

To be assigned

INTERNATIONAL APPLICATION NO.  
PCT/JP99/04503INTERNATIONAL FILING DATE  
20 August 1999PRIORITY DATE CLAIMED  
21 August 1998

TITLE OF INVENTION

DESCRIPTION QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF

APPLICANT(S) FOR DO/EO/US

Harukazu FUKAMI, Akiko ITO and Seiichi IMAJO

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
- ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern other document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
  - ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

PCT Request with a copy of the application as originally filed  
Form PCT/IB/308  
Cover page from the published PCT application (WO 00/10982)  
Form PCT/IB/332  
Amendment filed May 19, 2000  
Form PCT/IPEA/416 and IPER

U.S. APPLICATION NO. (If known) <b>097763213</b> To be assigned	INTERNATIONAL APPLICATION NO. <b>PCT/JP99/04503</b>	ATTORNEY'S DOCKET NUMBER <b>001560-390</b>
--------------------------------------------------------------------	--------------------------------------------------------	-----------------------------------------------

17. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b>	PTO USE ONLY
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b>  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1,000.00 (960)  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00 (970)  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00 (958)  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00 (956)  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 (962)					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$ 860.00</b>	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). 20 <input type="checkbox"/> 30 <input checked="" type="checkbox"/>				<b>\$ 130.00</b>	
Claims	Number Filed	Number Extra	Rate		
Total Claims	20 -20 =	0	0 X \$18.00 (966)	\$	
Independent Claims	3 -3 =	0	0 X \$80.00 (964)	\$	
Multiple dependent claim(s) (if applicable)			+ \$270.00 (968)	\$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 990.00</b>	
Reduction for 1/2 for filing by small entity, if applicable (see below).				\$	
<b>SUBTOTAL =</b>				<b>\$ 990.00</b>	
Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$	
<b>TOTAL NATIONAL FEE =</b>				<b>\$ 990.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property +				\$	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 990.00</b>	
				Amount to be: refunded	\$
				charged	\$

- a. ☐ Small entity status is hereby claimed.
- b. ☒ A check in the amount of \$ 990.00 to cover the above fees is enclosed.
- c. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- d. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Ronald L. Grudziecki  
 BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
 P.O. Box 1404  
 Alexandria, Virginia 22313-1404  
 (703) 836-6620

  
 SIGNATURE

Donna M. Meuth  
 NAME

36,607

REGISTRATION NUMBER

February 20, 2001

Patent  
Attorney's Docket No. 001560-390

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
 )  
Harukazu FUKAMI et al ) Group Art Unit: To be assigned  
 )  
Application No.: To be assigned ) Prior Examiner: To be assigned  
 )  
Filed: February 20, 2001 )  
 )  
For: DESCRIPTION QUINAZOLINE )  
 )  
DERIVATIVES AND )  
 )  
PHARMACEUTICAL )  
 )  
APPLICATIONS THEREOF )

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to the examination of the above-identified patent application, please enter the following amendments.

**IN THE ABSTRACT**

A new Abstract is enclosed.

**IN THE CLAIMS**

The claims were amended during the international stage pursuant to PCT Article 34.  
Please further amend the claims as follows.

Please delete claims 7-10 without prejudice or disclaimer.

Claim 3, line 2, delete "or 2".

Claim 4, lines 2-3, change "any one of claims 1 to 3" to --claim 1--.

Claim 5, line 4, change "any one of claims 1 to 4" to --claim 1--.

Claim 6, line 3, change "any one of claims 1 to 4" to --claim 1--.

09/763213 04400

Please add new claims 14-24 as follows.

--14. A method for prevention or treatment of allergic diseases or rheumatic diseases comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

15. A method for prevention or treatment of bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriosis or rheumatoid arthritis comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

16. A method for prevention or treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Angiotensin II production comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

17. A method for prevention or treatment of cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory diseases, revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including cardiac infarction, angioendothelia or vascular disorders accompanying arterialization and atheroma comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

18. A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 2, wherein, in the formula (1),  $R^2$  is a carboxylic acid group or a hydrogen atom.

19. A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 18, wherein  $R^3$  in the formula (1),  $R^2$  is a hydrogen atom.

20. A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 2, and a pharmaceutically acceptable carrier therefor.

21. A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 3, and a pharmaceutically acceptable carrier therefor.

22. A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 4, and a pharmaceutically acceptable carrier therefor.

23. A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 18, and a pharmaceutically acceptable carrier therefor.

24. A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 19, and a pharmaceutically acceptable carrier therefor.--

**REMARKS**

Prior to examination of the above-identified application, entry of the foregoing, and consideration of the above amendments are respectfully requested.

The claims have been amended to delete the multiple dependency. Method of prevention and treatment claims have also been added. Support for these claims may be found at the very least in claims 7-10. No new matter is thus being added.

Favorable action in the form of a Notice of Allowance is respectfully requested.

In the event that there are any questions relating to this amendment, or to the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney at 508-339-3684 concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Donna M. Meuth

Registration No. 36,607

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: February 20, 2001

	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

[illegible]

DESCRIPTION

QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL  
APPLICATIONS THEROF

TECHNICAL FIELD

5 The present invention relates to a quinazoline  
 derivative having a chymase inhibitory activity and a  
 pharmaceutically acceptable salt thereof and to a  
 pharmaceutical composition and a chymase inhibitor having  
 the same as an effective ingredient. The present  
 10 invention also relates to a method for producing the  
 quinazoline derivative and a synthesis intermediate  
 thereof.

BACKGROUND ART

15 Chymase is known to be present in secretory granules  
 of mast cells (MC), which are closely related to  
 inflammation, as one type of inflammatory cell. Further,  
 human chymase similarly is mainly present broadly in MCs  
 in the skin, heart, vascular walls, intestines, and other  
 tissue (*Mast Cell Proteases in Immunology and Biology*;  
 20 Caughey, G. H., ed; Marcel Dekker, Inc.: New York, 1995).  
 Human MCs are known to increase with bronchial asthma,  
 allergic dermatitis and other allergic diseases,  
 arteriosclerosis (Kaartinen et al., *Circulation*, 1994,  
 90, 1669), myocardial infarction (Kovanen et al.,  
 25 *Circulation*, 1995, 92, 1084), and other circulatory  
 system diseases and rheumatoid arthritis (Gotis-Graham et  
 al., *Arthritis Rheum.*, 1997, 40, 479). Further, it has  
 been reported that the genetic polymorphism of chymase is  
 correlated to the onset of eczema (Mao et al., *Lancet*,  
 30 1996, 348, 581). Human chymase produces angiotensin II  
 (Ang II) specifically from angiotensin I (Ang I) in the  
 same way as an angiotensin converting enzyme. Ang II is  
 closely related to regulation of the blood pressure,  
 diuretic regulation, the migration and proliferation of  
 35 smooth muscle cells etc. in the cardiovascular system  
 tissue, the growth of the extracellular matrix, and other  
 hypertrophy and remodeling of the cardiovascular system

09/763213-0401



(Hideki Okunishi; *Naibunpitsu-Tonyobyoka*, 1996, 3(6), 535). Human chymase is reported to have the following actions due to its protease activity in addition to production of Ang II: 1) degradation of the extracellular matrix (Vartio et al., *J. Biol. Chem.*, 1981, 256, 471), activation of collagenase (Kovanen et al., *J. Biol. Chem.*, 1994, 269, 18134), and production of collagen (Kofford et al., *J. Biol. Chem.*, 1997, 272, 7127); 2) causing release of inflammatory cytokine, for example, release of TGF  $\beta$ 1 from extracellular matrix (Taipale et al., *J. Biol. Chem.*, 1995, 270, 4689) and production of IL-1 $\beta$  (Mizutani et al., *J. Exp. Med.*, 1991, 174, 821); and 3) activation of stem cell factor (SCF) causing differentiation and proliferation of MCs (Longley et al., *Pro. Nat. Acad. Sci.*, 1997, 94, 9017). Further, rat MC chymase is known to cause degranulation of MCs through IgE receptors, release chemical mediators such as histamine, partially hydrolyze the apolipoproteins of low density lipoproteins (LDL) to make modified LDL incorporated into macrophages, and convert the macrophages to foam cells (*Mast Cell Proteases in Immunology and Biology*; Caughey, G. H., Ed; Marcel Dekker, Inc.: New York, 1995).


On the other hand, low molecular chymase inhibitors have already been shown in print (*Protease Inhibitors*; Barrett et. al., eds.; Elsevier Science B. V.: Amsterdam, 1986). Further, recently, as peptide inhibitors for human chymase, there have been  $\alpha$ -keto acid derivatives (WO-A-93-25574, *Proc. Natl. Acad. Sci. USA*, 1995, 92, 6738) and  $\alpha,\alpha$ -difluoro- $\beta$ -keto acid derivatives (JP-A-9-124691), while as peptide-mimetic inhibitors, there are trifluoromethylketone derivatives (WO-A-96-33974, JP-A-10-53579), and  $\alpha,\alpha$ -difluoro- $\beta$ -keto acid derivatives (JP-A-10-7661), while as nonpeptide inhibitors, there have been imidazolidinedione derivatives

The above reports relating to chymase suggest that chymase plays an important role in the process of inflammation, repair, and cure of damaged tissue. That is, it breaks down the extracellular matrix at the inflammatory tissue, releases and activates inflammatory cytokine, causes cell migration and proliferation, reproduces the extracellular matrix, and makes the tissue repair. The excess reactions in this process are believed to be linked to various diseases. Therefore, by inhibiting chymase and suppressing the exacerbation of vascular permeability induced by chymase, utilization as a medicament for prevention and a medicament for treatment of allergic diseases such as bronchial asthma, cnidosis, atopic dermatitis, mastocytosis, scleriosis, rheumatic diseases such as arthritis, cardiac and circulatory system diseases arising due to abnormal exacerbation of Ang II production, for example, cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory disorders, revasoconstriction after PCTA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including myocardial infarction, angioendothelia, or vascular disorders accompanying arterialization or atheroma may be given as examples.

30           Accordingly, the object of the present invention is  
to provide a compound having a chymase inhibitory  
activity and capable of suppressing the advance of  
vascular permeability induced by chymase and useful as a  
pharmaceutical composition and a pharmaceutical  
35           composition containing the same.

In accordance with the present invention, there is provided a quinazoline derivative having the following

formula (1) and a pharmaceutically acceptable salt thereof:



wherein, the ring A represents an aryl group;

10  $R^1$  represents a hydroxyl group, an amino group, a  $C_1$  to  $C_4$  lower alkylamino group which may be substituted with a carboxylic acid group, a  $C_7$  to  $C_{10}$  lower aralkylamino group which may be substituted with a carboxylic acid group, an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a  $C_1$  to  $C_4$  lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, a  $C_1$  to  $C_4$  lower alkyl group substituted with a carboxylic acid group, or a  $C_2$  to  $C_4$  lower alkylene group which may be substituted with a carboxylic acid group;

15

20

25

30

$R^2$  and  $R^3$  may be the same or different and represent a hydrogen atom, an unsubstituted or substituted  $C_1$  to  $C_4$  lower alkyl group, a halogen atom, a hydroxyl group, a  $C_1$  to  $C_4$  lower alkoxy group, an amino group, an unsubstituted or substituted  $C_1$  to  $C_4$  lower alkylamino group, an unsubstituted or substituted  $C_7$  to  $C_{10}$  aralkylamino group, an amino group acylated with a  $C_1$

35

to C<sub>4</sub> lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, or a carboxylic acid group or

when the ring A is a benzene ring, R<sup>1</sup> and R<sup>2</sup> may form, together with the substituting benzene ring, a fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group and R<sup>3</sup> is the same as defined above; and

X represents a hydrogen atom, a C<sub>1</sub> to C<sub>4</sub> lower alkyl group, a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, a halogen atom, a hydroxyl group, an amino group, or a nitro group.

The present compound has a human chymase inhibitory activity and suppresses the exacerbation of vascular permeability induced by chymase and is useful as a pharmaceutical composition for the prevention or treatment of allergic diseases or rheumatic diseases caused by the increase in mast cells or cardiac and circulatory system diseases due to the abnormal exacerbation of angiotensin II production.

In accordance with the present invention, there is also provided a pharmaceutical composition comprising, as an effective ingredient, the above-mentioned quinazoline derivative or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable conventional carrier therefor.

In accordance with the present invention, there is

09763213.041201

further provided a method for producing the quinazoline derivative and a synthesis intermediate thereof.

#### BEST MODE FOR CARRYING OUT THE INVENTION

5 In the general formula (1), preferable examples of the aryl group represented by the ring A are a benzene ring and a naphthalene ring.

Preferable examples of the C<sub>1</sub> to C<sub>4</sub> lower alkylamino group which may be substituted with the carboxylic acid group and the C<sub>7</sub> to C<sub>12</sub> lower aralkylamino group which may be substituted with a carboxylic acid group represented by R<sup>1</sup> are a methylamino group, an ethylamino group, a propylamino group, a butylamino group, a carboxymethylamino group, a carboxyethylamino group, a carboxypropylamino group, a carboxybutylamino group, a benzylamino group, a phenethylamino group, a phenylpropylamino group, a phenylbutylamino group, a carboxybenzylamino group, a carboxyphenethylamino group, a carboxyphenylpropylamino group, a carboxyphenylbutylamino group, etc.

20 Preferable examples of the amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a carboxylic acid group, the amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, and the amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group represented by R<sup>1</sup> are a formylamino group, an acetylamino group, a propionylamino group, a butyrylamino group, a benzoylamino group, a naphthoylamino group, a pyridinecarbonylamino group, a pyrrolecarbonylamino group, a carboxyacetylamino group, a carboxypropionylamino group, a carboxybutyrylamino group, a carboxybenzoylamino group, a carboxynaphthoylamino group, a carboxypyridinecarbonylamino group, a carboxypyrrolecarbonylamino group, etc.

35 Preferable examples of the amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be

0953213-041201

substituted with a carboxylic acid group, the amino group  
sulfonylated with an aromatic ring sulfonic acid which  
may be substituted with a carboxylic acid group, and the  
amino group sulfonylated with a heteroaromatic ring  
5 sulfonic acid which may be substituted with a carboxylic  
acid group represented by  $R^1$  are a methanesulfonylamino  
group, an ethanesulfonylamino group, a  
propanesulfonylamino group, a butanesulfonylamino group,  
a benzenesulfonylamino group, a naphthalenesulfonylamino  
10 group, a pyridinesulfonylamino group, a  
pyrrolesulfonylamino group, a carboxymethanesulfonylamino  
group, a carboxyethanesulfonylamino group, a  
carboxypropanesulfonylamino group, a carboxybutane-  
sulfonylamino group, a carboxybenzenesulfonylamino group,  
15 a carboxynaphthalenesulfonylamino group, a  
carboxypyridinesulfonylamino group, a  
carboxypyrrolesulfonylamino group, etc.

Preferable examples of the  $C_1$  to  $C_4$  lower alkyl  
group substituted with a carboxylic acid group  
20 represented by  $R^1$  are an acetic acid group, a propionic  
acid group, a butyric acid group, a valeric acid group,  
etc.

Preferable examples of the  $C_2$  to  $C_4$  lower alkylene  
group substituted with a carboxylic acid group  
25 represented by  $R^1$  are an acrylic acid group, a crotonic  
acid group, etc.

Preferable examples of the unsubstituted or  
substituted  $C_1$  to  $C_4$  lower alkyl group represented by  $R^2$   
or  $R^3$  are a straight-chain alkyl group such as a methyl  
30 group, an ethyl group, a n-propyl group, and a n-butyl  
group and a branched alkyl group such as an isopropyl  
group, a sec-butyl group, and a t-butyl group.

Preferable examples of the substituent group of the  
 $C_1$  to  $C_4$  lower alkyl group are a carboxylic acid group, a  
35 halogen atom such as a fluorine atom and a chlorine atom,  
a  $C_1$  to  $C_4$  lower alkoxy group, an amino group, a  
methylamino group, a dimethylamino group, a

carboxymethylamino group, a carboxyethylamino group, etc.

Preferable examples of the halogen atom represented by  $R^2$  or  $R^3$  are a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.

5        Preferable examples of the  $C_1$  to  $C_4$  lower alkoxy group represented by  $R^2$  or  $R^3$  are a straight-chain alkyloxy group such as a methoxy group, an ethoxy group, a n-propyloxy group, and a n-butoxy group and a branched alkyloxy group such as an isopropyloxy group, a sec-  
10       butoxy group, and a t-butoxy group.

Preferable examples of the unsubstituted or substituted  $C_1$  to  $C_4$  lower alkylamino group represented by  $R^2$  or  $R^3$  are a methylamino group, an ethylamino group, a propylamino group, a butylamino group, etc.

15       Preferable examples of the substituent group of the  $C_1$  to  $C_4$  lower alkylamino group are a carboxylic acid group, a halogen atom such as a fluorine atom and a chlorine atom, a  $C_1$  to  $C_4$  lower alkoxy group, etc.

Preferable examples of the unsubstituted or  
20       substituted  $C_7$  to  $C_{12}$  lower aralkylamino group represented by  $R^2$  or  $R^3$  are a benzylamino group, a phenethylamino group, a phenylpropylamino group, a phenylbutylamino group, etc.

Preferable examples of the substituent group of the  
25       aralkylamino group are a carboxylic acid group, a halogen atom such as a fluorine atom and a chlorine atom, a  $C_1$  to  $C_4$  lower alkoxy group, etc.

Preferable examples of the amino group acylated with  
30       a  $C_1$  to  $C_4$  lower aliphatic acid which may be substituted with a carboxylic acid group, the amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, and the amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group  
35       represented by  $R^2$  or  $R^3$  are a formylamino group, an acetylamino group, a propionylamino group, a butyrylamino group, a benzoylamino group, a naphthoylamino group, a

pyridinecarbonylamino group, a pyrrolecarbonylamino group, a carboxyacetylamino group, a carboxypropionylamino group, a carboxybutyrylamino group, a carboxybenzoylamino group, a carboxynaphthoylamino group, a carboxypyridinecarbonylamino group, a carboxypyrrolecarbonylamino group, etc.

Preferable examples of the amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a carboxylic acid group, the amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, and the amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group represented by R<sup>2</sup> or R<sup>3</sup> are a methanesulfonylamino group, an ethanesulfonylamino group, a propanesulfonylamino group, a benzenesulfonylamino group, a naphthalenesulfonylamino group, a pyridinesulfonylamino group, a pyrrolesulfonylamino group, a carboxymethanesulfonylamino group, a carboxyethanesulfonylamino group, a carboxypropanesulfonylamino group, a carboxybenzenesulfonylamino group, a carboxynaphthalenesulfonylamino group, a carboxypyridinesulfonylamino group, a carboxypyrrolesulfonylamino group, etc.

Preferable examples of the fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group which R<sup>1</sup> and R<sup>2</sup> form together with the substituting benzene ring when the ring A is a benzene ring, are a tetrahydroquinoline ring and a benzoxazine ring, for example, a tetrahydroquinoline, a benzoxazine, a quinoxaline, a benzodioxane, a carboxytetrahydroquinoline, a carboxybenzoxazine, a carboxyquinoxaline, a carboxybenzodioxane, etc.

Preferable examples of the C<sub>1</sub> to C<sub>4</sub> lower alkyl group represented by X are a straight-chain alkyl group



such as a methyl group, an ethyl group, a n-propyl group, and a n-butyl group and a branched alkyl group such as an isopropyl group, a sec-butyl group, and a t-butyl group.

Preferable examples of the C<sub>1</sub> to C<sub>4</sub> lower alkoxy group represented by X are a straight-chain alkyloxy group such as a methoxy group, an ethoxy group, a n-propyloxy group, and a n-butoxy group and a branched alkyloxy group such as an isopropyloxy group, a sec-butoxy group, and a t-butoxy group.

Preferable examples of the halogen atom represented by X, are a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.

Further, examples of a pharmaceutically acceptable salts are an acid salt such as a hydrochloric acid salt, a methanesulfonic acid salt, and a trifluoroacetic acid salt and an alkali metal salt such as a sodium salt and a potassium salt.

The quinazoline derivative having the formula (1) according to the present invention may, for example, be synthesized by the following Synthesis Method (A) or (B).

Synthesis Method (A)

A compound having the formula (2):




wherein the ring A is the same as defined above and R<sup>1'</sup>, R<sup>2'</sup> and R<sup>3'</sup> represent R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>, which may be protected with a protecting group, respectively, and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> represent the same as defined above

is reacted with an anthranilic acid derivative having the formula (3):



wherein X' represents X, which may be protected with a protecting group, and X represents the same as defined above

using the method described, for example, in JP-A-6-199839 to obtain a sulfonylurea derivative having the formula (4):



wherein the ring A, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and X' represent the same as defined above,

then, a condensing agent for example, 1,1'-carbonyldiimidazole (hereinafter referred to as CDI) is used to obtain the quinazoline ring, and if necessary, the protecting groups of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and X are deprotected.

In this reaction, when R<sup>1</sup>, R<sup>2</sup> or R<sup>3</sup> represents a group containing a hydroxyl group, an amino group, or a carboxylic acid group, R<sup>1</sup>, R<sup>2</sup> or R<sup>3</sup> may be optionally protected by a protecting group such as a benzyloxycarbonyl group, a t-butoxycarbonyl group, a benzyl group, an allyl group, a t-butyl group, etc. When X represents a hydroxyl group or an amino group, X may be optionally protected with a protecting group such as a benzyloxycarbonyl group, a t-butoxycarbonyl group, a benzyl group, an allyl group, a t-butyl group, etc.

The compound having the formula (2) used in this reaction includes a commercially available or known compound or a compound which can be synthesized by a known method may be used. For example, using the

synthesis method described in the specification of European Patent No. 0269141, it is possible to use a compound which can be synthesized from the corresponding sulfonamide derivative using chlorosulfonyl isocyanate.

5 For example, it is possible to use 3-allyloxycarbonyl-methylbenzenesulfonyl isocyanate, 4-allyloxycarbonyl-methylbenzenesulfonyl isocyanate, 4-allyloxybenzenesulfonyl isocyanate, etc.

10 As the anthranilic acid derivative having the formula (3) used for this reaction, a commercially available or known compound or a compound which can be synthesized by a known method may be used. For example, anthranilic acid, 4-chloroanthranilic acid, 4-methoxyanthranilic acid, 5-chloroanthranilic acid, 4-15 hydroxyanthranilic acid, etc. may be used.

20 The reaction to obtain the quinazoline ring from the sulfonylurea derivative having the formula (4) may be carried out using an aprotic solvent such as, for example, an ether solvent such as tetrahydrofuran and dioxane, a halogen-containing solvent such as methylene chloride, or dimethylformamide etc. at a temperature of -50°C to 50°C, preferably -20°C to room temperature. Further, for the cyclization reaction, it is possible to use an ordinary condensing agent which includes, for 25 example, CDI, dicyclohexylcarbodiimide, and similar carbodiimide compounds, mixed anhydrides, etc. The deprotecting reaction can be carried out by an ordinary method using hydrolysis with an acid or alkali, reduction or oxidation etc.

30 Synthesis Method (B)

A compound having the formula (5):




wherein the ring A, R<sup>1'</sup>, R<sup>2'</sup> and R<sup>3'</sup> represent the same as defined above

is condensed with an anthranilic acid derivative having the formula (6):



wherein X' represents the same as defined above, Ph represents a phenyl group, and R<sup>4</sup> represents a protecting group of the carboxyl group, which is specifically a group capable of being released by hydrolysis or hydrogenolysis, such as, for example, a methyl group, an ethyl group, or a benzyl group

using, for example, 1,8-diazabicyclo[5,4,0]-7-undecene (hereinafter referred to as DBU) to form a sulfonylurea derivative having the formula (7):



wherein the ring A, R<sup>1'</sup>, R<sup>2'</sup>, R<sup>3'</sup>, R<sup>4</sup> and X' are the same as defined above,

which is then hydrolyzed with an alkali or hydrogenolyzed to derive a corresponding carboxylic acid represented by the formula (4), then the quinazoline ring

is obtained and optionally the protecting groups of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and X are deprotected, in the same way as in Synthesis Method (A). In this reaction, when R<sup>1</sup>, R<sup>2</sup> or R<sup>3</sup> represents a group containing a hydroxyl group, an amino group, or a carboxylic acid group, R<sup>1</sup>, R<sup>2</sup> or R<sup>3</sup> may be optionally protected by a protecting group such as a benzyloxycarbonyl group, a t-butoxycarbonyl group, a benzyl group, an allyl group, a t-butyl group, etc. When X represents a hydroxyl group or an amino group, X may be optionally protected with a protecting group such as a benzyloxycarbonyl group, a t-butoxycarbonyl group, a benzyl group, an allyl group, a t-butyl group, etc.

As the compound having the formula (5) used in the reaction, a commercially available or known compound or a compound which can be synthesized by a known method may be used. For example, 3-hydroxybenzenesulfonamide, 2-aminobenzenesulfonamide, 3-aminobenzenesulfonamide, 4-aminobenzenesulfonamide, (±)-2-(4-aminosulfonylphenyl)butyric acid, 3-benzyloxycarbonylamino-4-chlorobenzenesulfonamide, 4-benzyloxycarbonylamino-3-chlorobenzenesulfonamide, 4-amino-3,5-dichlorobenzenesulfonamide, 3-benzyloxycarbonylamino-4-methylbenzenesulfonamide, 4-t-butoxycarbonyl-3-hydroxybenzenesulfonamide, 3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonamide, 4-t-butoxycarbonyl-3-hydroxybenzenesulfonamide, 3-t-butoxycarbonyl-4-hydroxybenzenesulfonamide, 3-acetamide-4-methoxybenzenesulfonamide, 3-(3-aminosulfonyl)phenylacrylic acid t-butylester, 3-amino-4-methoxybenzenesulfonamide, 4-methoxy-3-methylsulfonylaminobenzenesulfonamide, 3-carboxy-4-hydroxy-2-naphthalenesulfonamide, 4-benzyloxycarbonylamino-3-t-butoxycarbonylbenzenesulfonamide, (±)-3-t-butoxycarbonyl-2-oxo-1H,3H-quinoline-7-sulfonamide, (±)-2-t-butoxycarbonyl-3-oxo-1,4-benzoxazine-6-sulfonamide, etc.

may be used.

As the anthranilic acid derivative having the formula (6) used in this reaction, a commercially available or known compound or a compound which can be synthesized by a known method may be used. For example, methyl 4-chloro-2-N-phenoxy-carbonylanthranilate, ethyl 4-chloro-2-N-phenoxy-carbonylanthranilate, benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate, methyl 5-chloro-2-N-phenoxy-carbonylanthranilate, ethyl 5-chloro-2-N-phenoxy-carbonylanthranilate, benzyl 5-chloro-2-N-phenoxy-carbonylanthranilate, methyl 4-methoxy-2-N-phenoxy-carbonylanthranilate, ethyl 4-methoxy-2-N-phenoxy-carbonylanthranilate, benzyl 4-methoxy-2-N-phenoxy-carbonylanthranilate, methyl 4-hydroxy-2-N-phenoxy-carbonylanthranilate, ethyl 4-hydroxy-2-N-phenoxy-carbonylanthranilate, benzyl 4-hydroxy-2-N-phenoxy-carbonylanthranilate, etc. may be used.

The reaction for obtaining the compound having the formula (5) and the anthranilic acid derivative having the formula (6) condense to obtain a sulfonylurea derivative having the formula (7), may be carried out using an aprotic solvent, for example, an ether solvent such as tetrahydrofuran or dioxane, a halogen-containing solvent such as methylene chloride, or dimethylformamide etc. at a temperature of  $-50^{\circ}\text{C}$  to  $50^{\circ}\text{C}$ , preferably  $-20^{\circ}\text{C}$  to room temperature. Further, as the usable for the condensation reaction, an organic strong base such as DBU, inorganic bases such as potassium carbonate, sodium carbonate, potassium hydroxide, and sodium hydroxide, or metal bases such as sodium hydride may be used.

In the reaction for alkali hydrolysis or hydrogenolysis of the sulfonylurea derivative having the formula (7) thus obtained to obtain the sulfonylurea derivative having the formula (4), ordinary hydrolysis conditions or hydrogenolysis conditions for esters may be used.

Note that the above reaction may be carried out

while protecting the functional groups not involved in the reaction. According to the type of the protecting group, the protection is removed by chemical reduction or other ordinary protection-removing reactions. For example, when the protecting group is a t-butyl group or t-butoxycarbonyl group, trifluoroacetic acid may be used, while when it is an allyl group, palladium catalysts such as tetrakis(triphenylphosphine)palladium (0) may be used.

The compound having the formula (1), wherein  $R^1$  represents an amino group acylated with a  $C_1$  to  $C_4$  lower aliphatic acid which may be substituted with a carboxylic acid, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid and an amino group acylated with an heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid, can be obtained from the compound having the formula (1), wherein  $R^1$  represents an amino group, by acylating the same with carboxylic acid, carboxylic acid chloride, carboxylic acid anhydride using an ordinary method.

The compound having the formula (1), wherein  $R^1$  represents an amino group sulfonylated with a  $C_1$  to  $C_4$  lower alkane sulfonic acid which may be substituted with a carboxylic acid, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid and an amino group sulfonylated with an heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid, can be obtained from the compound having the formula (1), wherein  $R^1$  represents an amino group, by sulfonylating the same with sulfonic acid or sulfonic acid chloride using an ordinary method.

The product obtained according to the above-mentioned processes can be purified by a method such as recrystallization or column chromatography.

If necessary, the compounds having the formula (1) of the present invention obtained according to the above-

mentioned processes can each be reacted with one of various acids or basis to convert the compound into their salt. Exemplary acids usable for the conversion of the compound having the formula (1) into their salts can include inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid; and organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, citric acid, lactic acid, maleic acid, fumaric acid, tartaric acid, acetic acid, adipic acid, palmitic acid and tannic acid. Exemplary usable basis for the conversion of the compound having the formula (1) into their salts can include sodium hydroxide, lithium hydroxide and potassium hydroxide.

Further, the compounds having the formula (1) according to the present invention include those containing asymmetric centers. Each racemic mixture can be isolated by one or more of various methods, whereby a single optically-active substance can be obtained. Usable methods include, for example:

(1) Isolation by optically active column.

(2) Isolation by recrystallization subsequent to conversion into a salt with an optically active acid or base.

(3) Isolation by a combination of the above methods (1) and (2).

The quinazoline derivative of the present invention has an inhibitory activity with respect to human chymase. Further, it suppresses the exacerbation of vascular permeability caused by chymase. Further, it exhibits a sufficient half-life in human plasma. Therefore, as an inhibitor for mast cell chymase including human chymase, it is expected to be useful as a medicament for the prevention or treatment of cardiac and circulatory system diseases due to abnormal production of Ang II and for the prevention or treatment of allergic diseases and rheumatoid arthritis.



To use the effective ingredient of the present invention as a pharmaceutical composition for the prevention or treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Ang II production and allergic diseases and rheumatic diseases which are related to mast cells, one or more of the compounds of the present invention may be mixed and formed into a form suitable for use in the method of administration by an ordinary method. Examples of preparation forms for oral administration include capsules, tablets, granules, fine granules, syrups, dry syrups, and other preparations, while examples of preparation forms for non-oral administration include injections and besides suppositories such as rectal suppositories and vaginal suppositories, transnasal preparations such as sprays and ointments, and percutaneous preparations such as tapes for percutaneous absorption.

The clinical dose of the compound according to the present invention varies according to the diseased condition, degree of seriousness, age, presence of complications, etc. and also varies according to its preparation form. In the case of oral administration, however, it may be dosed usually, in terms of effective ingredients, as 1 to 1000 mg per adult per day. In the case of non-oral administration, it is sufficient to administer 1/10 to 1/2 the amount of the case of oral administration. These dosages can be suitably adjusted according to the age, the diseased condition, and the like of the patient to be dosed.

The toxicity of the compound according to the present invention is low. The acute toxicity values LD<sub>50</sub> at 24 hours after oral administration to 5-week old male mice were 1 g/kg or more.

#### EXAMPLES

The present invention will now be further explained by, but is by no means limited to, the following

Examples, but the scope of the invention is not limited to these Examples needless to say.

Example 1: Synthesis of 7-chloro-3-(3-hydroxybenzenesulfonyl)-2,4(1H,3H)-quinazolinedione  
(Compound 1)

Following the Synthesis Method (B), 938 mg (5.42 mmol) of 3-hydroxybenzenesulfonamide was dissolved in 40 ml of tetrahydrofuran, then 892  $\mu$ l (5.96 mmol) of 1,8-diazabicyclo[5,4,0]-7-undecene (hereinafter referred to as DBU) was added dropwise. The reaction solution was stirred at room temperature for 15 minutes, then 1.66 g (5.42 mmol) of methyl 4-chloro-2-N-phenoxy-carbonylanthranilate was added and the mixture was stirred at room temperature overnight. An excess amount of water was poured into the reaction solution, then the mixture was made acidic with hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with water and saturated saline, dried over anhydrous magnesium sulfate, and concentrated. The crude product thus obtained was purified by silica gel column chromatography (0% to 5% methanol/ dichloromethane) to obtain 1.23 g (yield 59%) of methyl 4-chloro-2-[(3-hydroxybenzenesulfonylamino)carbonyl]amino} benzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.91 (3H, s), 7.02 (1H, m), 7.09 (1H, m), 7.34 (1H, t), 7.57 (2H, m), 7.89 (1H, d), 8.38 (1H, d), 10.94 (1H, s). Next, the 1.23 g (3.2 mmol) of the compound thus obtained was dissolved in 20 ml of methanol, then 10 ml of 2N sodium hydroxide aqueous solution was added dropwise. The reaction solution was stirred at room temperature for 15 minutes, then an excess amount of water was added and the mixture was made acidic with hydrochloric acid. This was then stirred to cause crystals to precipitate which were then obtained by filtration and dried to obtain carboxylic acid. The product thus obtained was dissolved in 50 ml of tetrahydrofuran (hereinafter referred to as

THF), then 434 mg (2.68 mmol) of CDI was added under ice cooling and the mixture was stirred for 30 minutes. The reaction solution was diluted with ethyl acetate, washed with water and saturated saline, and dried over anhydrous magnesium sulfate, then concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:2) to obtain 230 mg (yield 20%: 2 steps) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 7.12 (2H, s), 7.24 (1H, d), 7.48 (1H, t), 7.58 (2H, s), 7.85 (1H, d), 10.28 (1H, s), 11.63 (1H, s).

Example 2: Synthesis of 3-(2-aminobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 2)

2.7 g (15.7 mmol) of 2-aminobenzenesulfonamide and 4.8 g (15.7 mmol) of methyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as Example 1 to obtain 3.2 g (yield 58%: 3 steps) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 6.46 (2H, s), 6.65 (1H, t), 6.81 (1H, d), 7.12 (1H, s), 7.23 (1H, d), 7.34 (1H, t), 7.76 (1H, d), 7.86 (1H, d).

Example 3: Synthesis of 7-chloro-3-(2-methylsulfonylaminobenzenesulfonyl)-2,4(1H,3H)-quinazolinedione (Compound 3)

22 mg (0.06 mmol) of Compound 2 was dissolved in 200  $\mu$ l of pyridine, 11.6  $\mu$ l (0.15 mmol) of methanesulfonyl chloride was added dropwise, then the resultant mixture was stirred at room temperature overnight. An excess amount of water was added to the reaction solution and the mixture was extracted with ethyl acetate. The organic layer was washed with 1N aqueous hydrochloric acid solution and saturated saline, then dried over anhydrous magnesium sulfate and concentrated to obtain a crude product. The crude product was crystallized from diethyl

ether to obtain 16 mg (0.04 mmol) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.61 (3H, s), 7.10 (1H, d), 7.20 (1H, d), 7.74 (1H, d), 7.82-7.90 (4H, m), 8.34 (1H, d), 11.70 (1H, s).

Example 4: Synthesis of 3-(4-aminobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 4)

2.7 g (15.7 mmol) of 4-aminobenzenesulfonamide and 4.8 g (15.7 mmol) of methyl 4-chloro-2-N-phenoxycarbonylanthranilate were treated in the same way as Example 1 to obtain 7.9 g (yield 94%) of methyl 2-[[[4-aminobenzenesulfonylamino)carbonyl]amino]-4-chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.59 (3H, s), 5.37 (2H, s), 6.45 (2H, d), 6.83 (1H, dd), 7.41 (2H, d), 7.81 (1H, d), 8.66 (1H, d), 9.64 (1H, s).

Then, from the resultant 7.9 g (14.8 mmol) of sulfonylurea product, in the same way, 4.3 g (yield 83%; 2 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 2.33 (3H, s), 6.93 (1H, m), 7.13 (1H, d), 7.23-7.26 (3H, m), 7.30 (1H, s), 7.86 (1H, d), 11.61 (1H, s).

Example 5: Synthesis of 3-(3-carboxymethyl-benzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 5)

Following the Synthesis Method (A), 3.27 g (11.6 mmol) of 3-allyloxycarbonylmethylbenzenesulfonyl isocyanate was dissolved in 100 ml of anhydrous THF, then 1.98 g (11.5 mmol) of 4-chloroanthranilic acid was added and the mixture was stirred at room temperature for 2 hours. The reaction solution was cooled with ice water, then 1.87 g (11.5 mmol) of CDI was added and the resultant mixture was stirred under ice cooling for 30 minutes. An excess amount of water was poured into the reaction solution, then the mixture was extracted with

ethyl acetate. The organic layer was washed, dried, and concentrated to obtain a crude product. This was crystallized with a small amount of ethyl acetate to obtain 2.0 g (yield 40%) of 3-(3-allyloxy-carbonylmethylbenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione. The allyl product thus obtained was dissolved in 100 ml of a formic acid-THF (1:9) mixture and 700 mg of triphenylphosphine was added. The reactor was shaded from light and under nitrogen atmosphere, then 700 mg of tetrakis(triphenylphosphine)palladium (0) was added and the resultant mixture was stirred while shaded at room temperature overnight. The reaction solution was concentrated in vacuo and the solid obtained was washed with methylene chloride to obtain 1.47 g (yield 81%) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.76 (2H, s), 7.13 (1H, s), 7.24 (1H, d), 7.61-7.69 (2H, m), 7.86 (1H, d), 8.05 (2H, s), 12.50 (1H, br).

Example 6: Synthesis of 3-(4-carboxymethyl-benzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 6)

1.10 g (3.95 mmol) of 4-allyloxycarbonylmethylbenzenesulfonyl isocyanate and 678 mg (3.95 mmol) of 4-chloroanthranilic acid were treated in the same way as in Example 5 to obtain 657 mg (yield 38%) of 3-(4-allyloxycarbonylbenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione. 538 mg (1.24 mmol) thereof was treated in the same way to obtain 342 mg of the above-identified compound (yield 70%). Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.75 (2H, s), 7.13 (1H, s), 7.23 (1H, d), 7.61-7.69 (2H, m), 7.86 (1H, d), 8.05 (2H, s), 12.07 (2H, br).

Example 7: Synthesis of (±)-2-{4-[(7-chloro-2,4(1H,3H)-quinazolin-3-yl)sulfonyl]phenyl}butyric acid (Compound 7)

1.02 g (3.41 mmol) of t-butyl (±)-2-(4-amino-sulfonylphenyl)butyrate acid and 1.04 g (3.41 mmol) of methyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as Example 1 to obtain 1.46 g (yield 84%) of methyl 2-[(4-[1-(t-butoxycarbonyl)propyl]benzenesulfonylamino)carbonyl]amino]-4-chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm,  $\text{CDCl}_3$ ): 0.89 (3H, t), 1.38 (9H, s), 1.69-1.76 (1H, m), 2.03-2.10 (1H, m), 3.42 (1H, t), 3.94 (3H, s), 7.04 (1H, d), 7.47 (2H, d), 7.93 (1H, d), 8.01 (2H, d), 8.45 (1H, br), 11.04 (1H, br).

Next, 4.3 ml (8.6 mmol) of 2N sodium hydroxide aqueous solution was used to similarly form carboxylic acid in an amount of 1.43 g and 463 mg (2.86 mmol) of CDI was used to obtain 970 mg (yield 71%; 2 steps) of t-butyl (±)-2-{4-[(7-chloro-2,4(1H,3H)-quinazolin-3-yl)sulfonyl]phenyl}butyrate.

Further, the t-butylester thus obtained was dissolved in 5 ml of dichloromethane, then 5 ml of trifluoroacetic acid was added and the resultant mixture was stirred at room temperature for 40 minutes. The reaction solution was concentrated in vacuo and the resultant crude product was washed with a small amount of diethyl ether to obtain 820 mg of the above-identified compound (yield 96%). Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 0.84 (3H, t), 1.67-1.75 (1H, m), 1.98-2.05 (1H, m), 3.62 (1H, t), 7.11 (1H, s), 7.24 (1H, d), 7.61 (2H, d), 7.86 (1H, d), 8.13 (2H, d), 11.62 (1H, s).

Example 8: Synthesis of 3-(3-amino-4-chlorobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 8)

1.0 g (2.93 mmol) of 3-benzyloxycarbonylamino-4-

chlorobenzenesulfonamide and 1.18 g (2.93 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as Example 1 to obtain 1.43 g (yield 78%) of benzyl 2-{[(3-benzoyloxycarbonylamino-4-chlorobenzene sulfonylamino)carbonylamino]-4-chlorobenzoate.

Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 5.19 (2H, s), 5.36 (2H, s), 7.21 (1H, dd), 7.34-7.48 (10H, m), 7.72-7.76 (2H, m), 7.97 (1H, d), 8.25 (1H, d), 8.30 (1H, d), 9.53 (1H, s), 10.30 (1H, s). 1.38 g (2.20 mmol) thereof was dissolved in 50 ml of THF, then 200 mg of palladium-carbon (10%) was added and the mixture was stirred under a hydrogen flow for 2 hours. The reaction mixture was filtered with Celite to remove the palladium-carbon, then the filtrate was concentrated in vacuo to obtain a carboxylic acid. The product obtained was suspended in 50 ml of THF, then 356 mg (2.20 mmol) of CDI was added under ice cooling and the resultant mixture was treated in the same way as Example 1 to obtain 560 mg (yield 66%: 2 steps) of the above-identified compound. Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 6.00 (2H, s), 7.12 (1H, s), 7.26 (2H, t), 7.48 (1H, d), 7.66 (1H, s), 7.86 (1H, d), 11.76 (1H, br).

Example 9: Synthesis of 3-(4-amino-3,5-dichlorobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 9)

1.06 g (4.40 mmol) of 4-amino-3,5-dichlorobenzenesulfonamide and 1.34 g (4.40 mmol) of methyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as Example 1 to obtain 905 mg (yield 44%) of methyl 2-{[(4-amino-3,5-dichlorobenzenesulfonylamino)carbonylamino]-4-chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.87 (3H, s), 6.59 (2H, br), 7.22 (1H, dd), 7.72 (2H, s), 7.93 (1H, d), 8.24 (1H, d), 10.17 (1H, s).

Then, from 905 mg (2.0 mmol) of the resultant sulfonylurea product, in the same way, 660 mg (yield 82%: 2 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 6.80 (2H, s), 7.12 (1H, s), 7.24 (1H, d), 7.86 (1H, d), 7.92 (2H, s), 11.63 (1H, br).

Example 10: Synthesis of 3-(3-amino-4-methylbenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 10)

960 mg (3.00 mmol) of 3-benzyloxycarbonylamino-4-methylbenzenesulfonamide and 1.14 g (3.00 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 8 to obtain 1.14 g (yield 62% of benzyl 2-[(3-benzyloxycarbonylamino-4-methylbenzenesulfonylamino)carbonyl]amino}-4-chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 2.30 (3H, s), 5.17 (2H, s), 5.36 (2H, s), 7.20 (1H, dd), 7.33-7.48 (11H, m), 7.63 (1H, d), 7.97 (1H, d), 8.11 (1H, s), 8.25 (1H, s), 9.27 (1H, s), 10.30 (1H, s), 12.20 (1H, br).

Then, from 1.14 g (1.87 mmol) of the resultant sulfonylurea product, in the same way, 190 mg (yield 27%: 2 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 2.12 (3H, s), 5.47 (2H, s), 7.12 (1H, s), 7.16-7.25 (3H, m), 7.38 (1H, s), 7.85 (1H, d), 11.58 (1H, s).

Example 11: Synthesis of 3-[(3-carboxymethylaminophenyl)sulfonyl]-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 11)

1.62 g (5.65 mmol) of 3-t-butoxycarbonyl-methylaminobenzenesulfonamide and 1.73 g (5.65 mmol) of methyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 7 to obtain 209 mg (yield 9%: 4 steps) of the above-identified compound.



Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.86 (2H, s), 6.88 (1H, s), 7.12 (1H, s), 7.24 (1H, d), 7.30-7.38 (3H, m), 7.86 (1H, d), 11.61 (1H, br).

5      Example 12: Synthesis of 3-(3-aminobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 12)

3.5 g (12.9 mmol) of 3-t-butoxycarbonylamino-benzenesulfonamide and 3.9 g (12.8 mmol) of methyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in  
10 the same way as in Example 7 to obtain 2.2 g (yield 49%: 4 steps) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 5.72 (2H, s), 6.87 (1H, d), 7.12 (1H, s), 7.23-7.27 (2H, m), 7.33 (1H, s), 7.86 (1H, d),  
15 11.61 (1H, s).

Example 13: Synthesis of 2-{3-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]phenylaminocarbonyl}propionic acid (Compound 13)

100 mg (0.28 mmol) of Compound 12 was dissolved in 5  
20 ml of THF, 100 mg (1.0 mmol) of succinic anhydride was added, and the resultant mixture was heated and refluxed for 3 hours. The reaction solution was concentrated in vacuo and the crude product thus obtained was crystallized with ethyl acetate-diethyl ether to obtain  
25 120 mg (yield 96%) of the above-identified compound. Properties: colorless crystal, Melting point: 187-188°C, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 2.54 (2H, d), 2.59 (2H, d), 7.12 (1H, s), 7.24 (1H, d), 7.59 (1H, t), 7.80 (1H, d), 7.86 (1H, d), 7.96 (1H, d), 8.41 (1H, s), 10.40 (1H, s), 11.63  
30 (1H, br), 12.10 (1H, br).

Example 14: Synthesis of 3-{3-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]phenyl}acrylic acid (Compound 14)

1.54 g (5.44 mmol) of t-butyl 3-(3-aminosulfonyl)phenylacrylate and 1.66 g (5.44 mmol) of methyl 4-chloro-2-N-phenoxy-carbonylanthranilate were

5 treated in the same way as in Example 7 to obtain 2.18 g  
(yield 81%) of methyl 2-([3-(3-t-butoxy-3-oxo-1-  
propenyl)benzenesulfonylamino]carbonyl)amino)-4-  
chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$   
ppm,  $\text{CDCl}_3$ ): 1.53 (9H, s), 3.95 (3H, s), 6.46 (1H, d),  
7.05 (1H, d), 7.55 (1H, m), 7.57 (1H, d), 7.72 (1H, m),  
7.93 (1H, m), 8.04 (1H, m), 8.27 (1H, s), 8.46 (1H, d),  
11.05 (1H, br).

10 Then, from 2.18 g (4.4 mmol) of the resultant  
sulfonylurea product, in the same way, 698 mg (yield 37%:  
3 steps) of the above-identified compound was obtained.  
Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$   
(decomposition), PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 6.65 (1H, d), 7.12  
(1H, s), 7.25 (1H, d), 7.69 (1H, d), 7.72 (1H, t), 7.87  
15 (1H, d), 8.12 (2H, q), 8.37 (1H, s), 11.64 (1H, s).

Example 15: Synthesis of 4-[(7-chloro-2,4(1H,3H)-  
quinazolinedion-3-yl)sulfonyl]salicylic acid (Compound  
15)

20 1.0 g (3.66 mmol) of 4-t-butoxycarbonyl-3-  
hydroxybenzenesulfonamide and 1.12 g (3.66 mmol) of  
methyl 4-chloro-2-N-phenoxy-carbonylanthranilate were  
treated in the same way as in Example 7 to obtain 1.79 g  
(yield 100%) of methyl 2-[(4-t-butoxycarbonyl-3-  
hydroxybenzenesulfonylamino)carbonyl]amino)-4-  
25 chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$   
ppm,  $\text{DMSO}-d_6$ ): 1.57 (9H, s), 3.87 (3H, s), 7.14 (1H, d),  
7.40-7.45 (2H, m), 7.85 (1H, d), 7.92 (1H, d), 8.32 (1H,  
d), 10.13 (1H, s), 10.82 (1H, s).

30 Then, from 1.78 g (3.66 mmol) of the resultant  
sulfonylurea product, in the same way, 370 mg (yield 25%:  
3 steps) of the above-identified compound was obtained.  
Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$   
(decomposition), PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 7.13 (1H, s), 7.26  
(1H, d), 7.69 (1H, d), 7.87 (1H, d), 8.01 (1H, d), 11.67  
35 (1H, s).

Example 16: Synthesis of 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]salicylic acid monosodium salt (Compound 16)

50 mg (0.13 mmol) of Compound 15 was suspended in approximately 1 ml of THF, then 126  $\mu$ l of 1N sodium hydroxide aqueous solution was added dropwise. The solution was confirmed to have become uniform, then 30 ml of water was added and the mixture freeze-dried to quantitatively obtain the above-identified compound in an amorphous state in an amount of 52 mg. Properties: colorless amorphous, PMR ( $\delta$  ppm,  $\text{CD}_3\text{OD}$ ): 7.11 (1H, s), 7.19 (1H, d), 7.58 (1H, d), 7.63 (1H, s), 7.92 (1H, d), 8.03 (1H, d).

Example 17: Synthesis of 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid (Compound 17)

2.84 g (6.99 mmol) of 3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonamide and 2.67 g (6.99 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 8 to obtain 3.74 g (yield 77%) of benzyl 2-[(3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonylamino)carbonylamino]-4-chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 1.54 (9H, s), 5.19 (2H, s), 5.34 (2H, s), 7.05 (1H, m), 7.34-7.58 (10H, m), 7.60 (1H, d), 7.90 (1H, d), 7.98 (1H, d), 8.50 (1H, br), 8.62 (1H, s), 10.00 (1H, br), 10.41 (1H, s).

Then, from 3.74 g (5.39 mmol) of the resultant sulfonylurea, in the same way, 690 mg (yield 30%: 2 steps) of t-butyl 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilate was obtained, then this was subjected to a similar debutylation reaction to obtain 503 mg (yield 84%) of the above-identified compound. Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 7.14 (1H, s), 7.18 (1H, d), 7.25 (1H, d), 7.59 (1H,

s), 7.87 (1H, d), 7.89 (1H, d), 11.62 (1H, s).

Example 18: Synthesis of 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid monosodium salt (Compound 18)

5           50 mg (0.13 mmol) of Compound 17 was suspended in approximately 1 ml of THF, then 126 µl of 1N sodium hydroxide aqueous solution was added dropwise. The solution was confirmed to have become uniform, then 30 ml of water was added and the mixture was freeze-dried to  
10           quantitatively obtain the above-identified compound in an amorphous state in an amount of 52 mg. Properties: colorless amorphous, PMR (δ ppm, DMSO-d<sub>6</sub>): 7.11-7.22 (3H, m), 7.37 (1H, s), 7.83 (1H, d), 7.91 (1H, d).

Example 19: Synthesis of 3-(4-hydroxybenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 19)

15           1.50 g (7.03 mmol) of 4-allyloxybenzenesulfonyl isocyanate and 1.2 g (7.03 mmol) of 4-chloroanthranilic acid were treated in the same way as in Example 5 to  
20           obtain 1.5 g (yield 53%) of 3-(4-allyloxybenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione. 500 mg (1.27 mmol) thereof was similarly treated to obtain 405 mg of the above-identified compound (yield 90%). Properties: colorless  
25           crystal, Melting point: >200°C (decomposition), PMR (δ ppm, DMSO-d<sub>6</sub>): 6.98 (2H, d), 7.11 (1H, s), 7.23 (1H, d), 7.85 (1H, d), 8.00 (2H, d), 11.25 (1H, br).

Example 20: Synthesis of 4-[(2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]salicylic acid (Compound 20)

30           618 mg (2.26 mmol) of 4-t-butoxycarbonyl-3-hydroxybenzenesulfonamide and 613 mg (2.26 mmol) of methyl 2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 792 mg (yield  
35           78%) of methyl 2-[(4-t-butoxycarbonyl-3-hydroxybenzenesulfonylamino)carbonyl]amino}benzoate. Properties:

colorless amorphous, PMR ( $\delta$  ppm,  $\text{CDCl}_3$ ): 1.60 (9H, s), 3.97 (3H, s), 7.09 (1H, t), 7.49-7.52 (2H, m), 7.65 (1H, d), 7.90 (1H, d), 8.01 (1H, dd), 8.33 (1H, d), 10.98 (1H, s), 11.18 (1H, s).

5 Then, from 790 mg (1.75 mmol) of the resultant sulfonylurea product, in the same way, 100 mg (yield 8%: 3 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 7.13 (1H, d), 7.22  
10 (1H, t), 7.63-7.69 (3H, m), 7.87 (1H, d), 8.01 (1H, d), 11.57 (1H, s).

Example 21: Synthesis of 5-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]salicylic acid (Compound 21)

15 320 mg (1.17 mmol) of 3-t-butoxycarbonyl-4-hydroxybenzenesulfonamide and 447 mg (1.17 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 611 mg (yield 93%) of benzyl 2-[(3-t-butoxycarbonyl-4-  
20 hydroxybenzenesulfonylamino)carbonylamino]-4-chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm,  $\text{CDCl}_3$ ): 1.62 (9H, s), 5.35 (2H, s), 7.01-7.05 (2H, m), 7.37-7.41 (5H, m), 7.96 (1H, d), 8.10 (1H, dd), 8.46-8.48 (2H, m), 10.99 (1H, s), 11.66 (1H, s).

25 Then, from 611 mg (1.09 mmol) of the resultant sulfonylurea product, in the same way, 114 mg (yield 33%: 3 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 7.11 (1H, s), 7.19  
30 (1H, d), 7.24 (1H, d), 7.86 (1H, d), 8.20 (1H, d), 8.56 (1H, s), 11.57 (1H, s).

Example 22: Synthesis of 3-(3-acetamide-4-methoxybenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 22)

35 500 mg (2.19 mmol) of 3-acetamide-4-methoxybenzenesulfonamide and 836 mg (2.19 mmol) of

benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 8 to obtain 812 mg (yield 70%) of benzyl 2-[[[3-acetylamino-4-methoxybenzenesulfonylamino)carbonyl]amino]-4-

chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 2.12 (3H, s), 3.93 (3H, s), 5.36 (2H, s), 7.20 (1H, d), 7.24 (1H, d), 7.36-7.48 (5H, m), 7.69 (1H, d), 7.96 (1H, d), 8.24 (1H, s), 8.67 (1H, s), 9.39 (1H, s), 10.25 (1H, s), 12.11 (1H, br).

Then, from 611 mg (1.09 mmol) of the resultant sulfonylurea product, in the same way, 250 mg (yield 39%; 2 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$

(decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 2.12 (3H, s), 3.95 (3H, s), 7.12 (1H, s), 7.23 (1H, d), 7.30 (1H, d), 7.85 (1H, d), 7.89 (1H, d), 8.80 (1H, s), 9.42 (1H, s), 11.59 (1H, br).

Example 23: Synthesis of 3-(3-amino-4-methoxybenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione (Compound 23)

400 mg (1.40 mmol) of 3-t-butoxycarbonylamino-4-methoxybenzenesulfonamide and 533 mg (1.40 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 86 mg (yield 16%; 4 steps) of the above-identified compound. Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.81 (3H, s), 7.26-7.37 (5H, m), 7.77 (1H, s), 7.90 (1H, d), 7.94 (1H, d), 11.73 (1H, s).

Example 24: Synthesis of 7-chloro-3-(4-methoxy-3-methylsulfonylamino)benzenesulfonyl)-2,4(1H,3H)-quinazolinedione (Compound 24)

500 mg (1.89 mmol) of 4-methoxy-3-methylsulfonylamino)benzenesulfonamide and 722 mg (1.89 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 8 to obtain

888 mg (yield 83%) of benzyl 2-({[(4-methoxy-3-methylsulfonylamino)benzene sulfonylamino]carbonyl}amino)-4-chlorobenzoate.

Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ):

2.12 (3H, s), 3.93 (3H, s), 5.36 (2H, s), 7.20 (1H, d), 7.24 (1H, d), 7.36-7.48 (5H, m), 7.69 (1H, d), 7.96 (1H, d), 8.24 (1H, s), 8.67 (1H, s), 9.39 (1H, s), 10.25 (1H, s), 12.11 (1H, br).

Then, from 880 mg (1.55 mmol) of the resultant sulfonylurea product, in the same way, 620 mg (yield 85%: 2 steps) of the above-identified compound was obtained.

Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$

(decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 3.04 (3H, s), 3.94 (3H, s), 7.11 (1H, s), 7.23 (1H, d), 7.34 (1H, d), 7.86 (1H, d), 7.99 (1H, d), 8.10 (1H, s).

Example 25: Synthesis of 4-[(7-chloro-2,4(1H,3H)-quinazolin-3-yl)sulfonyl]-1-hydroxy-naphthalene-2-carboxylic acid (Compound 25)

323 mg (1.00 mmol) of 3-t-butoxycarbonyl-4-hydroxy-1-naphthalenesulfonamide and 381 mg (1.00 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 447 mg (yield 73%) of 4-({[(2-benzyloxycarbonyl-5-chloroanilino)carbonyl]amino}sulfonyl)-1-hydroxy-2-naphthalenecarboxylic acid t-butyl ester. Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 1.66 (9H, s), 5.34 (3H, s), 6.98 (1H, d), 7.35-7.48 (5H, m), 7.66 (1H, m), 7.81 (1H, m), 7.89 (1H, d), 8.37 (2H, m), 8.44 (1H, s), 8.71 (1H, d), 10.02 (1H, br), 12.52 (1H, br).

Then, from 445 mg (0.72 mmol) of the resultant sulfonylurea product, in the same way, 56 mg (yield 18%: 3 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 7.08 (1H, s), 7.20 (1H, d), 7.63 (1H, t), 7.77 (1H, t), 7.84 (1H, d), 8.42 (1H, d), 8.51 (1H, d), 8.75 (1H, s), 11.57 (1H, s).

Example 26: Synthesis of 5-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid (Compound 26)

834 mg (2.05 mmol) of 4-benzyloxycarbonylamino-3-t-butoxycarbonylbenzenesulfonamide and 783 mg (2.05 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 1.18 g (yield 83%) of benzyl 2-[(4-benzyloxycarbonylamino-3-t-butoxycarbonylbenzenesulfonylamino)carbonyl]amino-4-chlorobenzoate. Properties: colorless amorphous, PMR ( $\delta$  ppm, CDCl<sub>3</sub>): 1.56 (9H, s), 5.22 (2H, s), 5.37 (2H, s), 7.04 (1H, dd), 7.33-7.42 (10H, m), 7.97 (1H, d), 8.14 (1H, d), 8.45 (1H, d), 8.60 (1H, d), 8.65 (1H, d), 11.01 (1H, s), 11.11 (1H, s).

Then, from 1.17 g (1.69 mmol) of the resultant sulfonylurea product, in the same way, 404 mg (yield 60%; 3 steps) of the above-identified compound was obtained. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO-d<sub>6</sub>): 6.89 (1H, d), 7.11 (1H, s), 7.23 (1H, d), 7.85 (1H, d), 7.98 (1H, d), 8.51 (1H, s), 11.51 (1H, s).

Example 27: Synthesis of 4-[(7-methoxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid (Compound 27)

500 mg (1.23 mmol) of 3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonamide and 460 mg (1.22 mmol) of benzyl 4-methoxy-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 15 mg (yield 3.1%; 4 steps) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO-d<sub>6</sub>): 3.82 (3H, s), 6.58 (1H, s), 6.80 (1H, d), 7.16 (1H, d), 7.56 (1H, s), 7.80 (1H, d), 7.90 (1H, d), 11.49 (1H, s).



Example 28: Synthesis of (±)-7-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]-2-oxo-1H,3H-quinoline-3-carboxylic acid (Compound 28)

400 mg (1.23 mmol) of (±)-3-t-butoxycarbonyl-2-oxo-1H,3H-quinoline-7-sulfonamide and 468 mg (1.23 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 649 mg (yield 86%) of 8-({[(2-benzyloxycarbonyl-5-chloroanilino)carbonyl]amino}sulfonyl)-2-oxo-1,2,3,4-tetrahydro-3-quinoline carboxylic acid t-butyl ester.

Properties: colorless amorphous, PMR ( $\delta$  ppm,  $\text{CDCl}_3$ ): 1.32 (9H, s), 3.18-3.30 (2H, m), 3.54 (1H, m), 5.35 (2H, s), 6.85 (1H, m), 7.00 (1H, m), 7.35-7.39 (5H, m), 7.87-7.96 (3H, m), 8.47 (1H, m), 8.78 (1H, br), 10.92 (1H, br).

Then, from 640 mg (1.04 mmol) of the resultant sulfonylurea product, in the same way, 258 mg (yield 55%: 3 steps) of the above-identified compound was obtained.

Properties: colorless crystal, Melting point:  $>200^\circ\text{C}$  (decomposition), PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 3.23-3.31 (2H, m), 3.59 (1H, t), 7.07 (1H, d), 7.12 (1H, s), 7.25 (1H, d), 7.86 (1H, d), 7.96 (1H, d), 7.98 (1H, d), 10.84 (1H, s), 11.60 (1H, s).

Example 29: Synthesis of (±)-6-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]-3-oxo-1,4-benzoxazine-2-carboxylic acid (Compound 29)

300 mg (0.91 mmol) of (±)-2-t-butoxycarbonyl-3-oxo-1,4-benzoxazin-6-sulfonamide and 349 mg (0.91 mmol) of benzyl 4-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 417 mg (yield 74%) of 5-({[(2-benzyloxycarbonyl-5-chloroanilino)carbonyl]amino}sulfonyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid t-butyl ester.

Properties: colorless amorphous, PMR ( $\delta$  ppm,  $\text{DMSO}-d_6$ ): 1.29 (9H, s), 5.37 (2H, s), 5.42 (2H, s), 7.19-7.26 (2H, m), 7.37-7.57 (7H, m), 7.97 (1H, d), 8.25 (1H, d), 10.27 (1H, s), 11.25 (1H, s), 12.22 (1H, br).

Then, from 417 mg (0.68 mmol) of the resultant sulfonylurea product, in the same way, 100 mg (yield 32%: 3 steps) of the above-identified compound was obtained.

Properties: colorless crystal, Melting point: >200°C

5 (decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 5.47 (1H, s), 7.11 (1H, s), 7.24 (1H, d), 7.29 (1H, d), 7.76 (1H, s), 7.78 (1H, d), 7.86 (1H, d), 11.25 (1H, s), 11.62 (1H, s).

10 Example 30: Synthesis of 4-[(7-hydroxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid (Compound 30)

620 mg (1.53 mmol) of 3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonamide and 550 mg (1.51 mmol) of benzyl 4-hydroxy-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 25 mg (yield 4%: 4 steps) of the above-identified compound.

Properties: colorless crystal, Melting point: >200°C

(decomposition), PMR ( $\delta$  ppm, DMSO- $d_6$ ): 6.48 (1H, s), 6.61 (1H, d), 7.14 (1H, d), 7.51 (1H, s), 7.70 (1H, d), 7.90 (1H, d), 10.80 (1H, s), 11.39 (1H, s).

20 Example 31: Synthesis of 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]-2-N-propionylantronic acid (Compound 31)

840 mg (1.86 mmol) of Compound 17 was dissolved in 8 ml of 1,4-dioxane, 240  $\mu$ l (2.79 mmol) of propionyl chloride was added dropwise, then the resultant mixture was stirred overnight at 60°C. An excess of water was added to the reaction solution and the mixture was extracted with ethyl acetate. The organic layer thus obtained was washed, dried, and concentrated to obtain a crude product of t-butyl 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]-2-N-propionylantronic acid. The obtained crude product was stirred at room temperature in 3 ml of trifluoroacetic acid for 1 hour, then the reaction solution was concentrated in vacuo to obtain a crude product. This was washed by diethyl ether to obtain 400 mg (yield 48%: 2 steps) of the above-

identified compound. Properties: colorless crystal,  
Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO-  
d<sub>6</sub>): 1.10 (3H, t), 2.45 (2H, dd), 7.11 (1H, s), 7.24 (1H,  
d), 7.85 (1H, d), 7.88 (1H, d), 8.17 (1H, d), 9.18 (1H,  
s), 11.07 (1H, s), 11.63 (1H, s).

Example 32: Synthesis of 4-[(6-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid (Compound 32)

300 mg (0.74 mmol) of 3-benzyloxycarbonylamino-4-t-butoxycarbonylbenzenesulfonamide and 310 mg (0.81 mmol) of benzyl 5-chloro-2-N-phenoxy-carbonylanthranilate were treated in the same way as in Example 17 to obtain 75 mg (yield 26%: 4 steps) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO-d<sub>6</sub>): 7.13-7.20 (2H, m), 7.56 (1H, s), 7.72 (1H, d), 7.82 (1H, s), 7.90 (1H, d), 11.68 (1H, s).

Example 33: Synthesis of 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]-2-N-methanesulfonylanthranilic acid (Compound 33)

200 mg (0.44 mmol) of Compound 17 was treated in the same way as in Example 3 to obtain 81 mg of t-butyl 4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]-2-N-methanesulfonylanthranilate. This was used to perform the same debutylation reaction to obtain 53 mg (yield 25%: 2 steps) of the above-identified compound. Properties: colorless crystal, Melting point: >200°C (decomposition), PMR ( $\delta$  ppm, DMSO-d<sub>6</sub>): 3.24 (3H, s), 7.11 (1H, s), 7.25 (1H, d), 7.85-7.91 (2H, m), 8.23 (1H, d), 8.39 (1H, s), 11.05 (1H, br), 11.70 (1H, s).

Example 34: Synthesis of 3-(3-aminobenzenesulfonyl)-7-chloro-2,4-(1H,3H)quinazolinedion methanesulfonic acid salt (Compound 34)

2.15 g (6.10 mmol) of compound 12 was dissolved in 65 ml of THF and 0.4 ml of methanesulfonic acid was added dropwise. To this solution, 200 ml of ether was added and

the resultant precipitate was filtered to obtain 2.59 g (yield 95%) of the above-identified compound. Properties: colorless amorphous, PMR ( $\delta$  ppm, DMSO- $d_6$ ): 2.35 (3H, s), 6.98 (1H, d), 7.12 (1H, m), 7.25 (1H, m), 7.34 (2H, s), 7.43 (1H, m), 7.86 (1H, s), 11.64 (1H, s)

Evaluation Example 1: Measurement of Chymase Inhibitory Activity

Human heart chymase was purified according to the method of Urata et al. (*J. Biol. Chem.*, 1990, 265, 22348). The inhibitory activity of the quinazoline derivatives of the present invention with respect to chymase was measured in the following manner. That is, the purified enzyme solution was diluted to a suitable concentration with 0.1M tris-hydrochloride buffer (pH=7.5), 1M sodium chloride, and 0.01% TritonX-100 to obtain an enzyme solution. A 10 mM dimethyl sulfoxide (hereinafter referred to as DMSO) solution of Suc-Ala-Ala-Pro-Phe-MCA (Peptide Institute) was diluted 20-fold at the time of use by 0.1M tris-hydrochlorate, 1M sodium chloride, and 0.01% TritonX-100 to obtain the substrate solution.

75  $\mu$ l of the enzyme solution warmed to 30°C was mixed with 5  $\mu$ l of DMSO solution of the test sample. The mixture was preincubated at 30°C for 10 minutes. Next, 20  $\mu$ l of a substrate solution warmed to 30°C was mixed with the test sample-enzyme mixture and incubated at 30°C. After 10 minutes, 50  $\mu$ l of 30% acetic acid was added to stop the enzymatic reaction. The amount of the AMC produced was quantified using a fluorescent photometer. At the same time, a blind test was carried out by adding, instead of the test sample solution, 5  $\mu$ l of DMSO and performing the same reaction. The chymase inhibitory activity was expressed by a rate of inhibition, that is, the 50% inhibition concentration ( $IC_{50}$ ), based on the blind test value.

The quinazoline derivatives of the present invention all strongly inhibited human chymase at concentrations of 100  $\mu$ M. The IC<sub>50</sub> values for typical compounds are shown in Table I.

5

Table 1

Example No.	IC <sub>50</sub> value ( $\mu$ M)	t <sub>1/2</sub> (min)
1	0.36	78
2	0.14	175
8	0.035	29
10	0.17	167
12	0.44	249
13	0.3	97
16	0.84	>240
17	0.14	260
18	0.14	103
21	0.34	-
22	0.3	104
24	0.32	79
27	4.0	263
29	1.7	>240
32	1.5	74
34	0.36	709

Evaluation Example 2: Test of Human Chymase Induced Vascular Permeability Exacerbation Reaction

10        Wister male rats (body weight 200 to 220 g, Charles River Japan) were used. In the backs of the rats from which the hair had been shaved off, 100  $\mu$ l (20 mU: 1U being amount of enzyme for producing 1 nmol of AMC in 1 minute from Suc-Ala-Ala-Pro-Phe-MCA at pH7.5 and 30°C) of  
15        a solution of the human chymase enzyme solution purified in Evaluation Example 1 diluted 100-fold by PBS (phosphate buffered saline) was injected intracutaneously, then immediately thereafter a 0.5% (w/v) Evans Blue solution was administered from the tail

artery. After 30 minutes, the rats were sacrificed by draining their blood under anesthesia with ether and the amount of dye leaking out to the back skin was measured. The region of the skin where the dye leaked out was cut off and 1.0 ml of 1N KOH solution was added and the resultant mixture was allowed to stand at 37°C overnight. Next, 4 ml of an acetone-0.6N phosphoric acid (13:5) mixture was added to extract the dye. The absorbance at 650 nm of the supernatant was measured. The calibration curve for measurement of the amount of the dye leaked out was prepared by injecting Evans Blue solution so as to give 10, 20, 30, 40, and 50 µg in the rat back skin and extracting the dye by the above method. Similarly, the amount of dye when administering intracutaneously 100 µl of the solution of the same composition but not containing human chymase was used as the control.

Next, 10 mg/kg of the compound of Example 18 was orally administered. 30 minutes later, 100 µl (20 mU) of human chymase the same as the non-drug administered group was injected intracutaneously and the amount of dye leaked out similarly measured. The rate of suppression of the amount of dye leakage due to the compound was calculated according to the following calculation formula. The rate of suppression for the compound of Example 18 was 64%.

Rate of suppression of amount of leakage of dye (%)  
= [(amount of leakage of dye of compound administered group - amount of leakage of dye of control group) ÷ (amount of leakage of dye of non-compound administered group - amount of leakage of dye of control group)] x 100

It is known that vascular permeability is exacerbated when inflammation is caused by an inflammation causing substance. Further, suppression of the exacerbation of vascular permeability has become one of the indicators for evaluation of anti-inflammation agents. In general, it is known that the histamine

released by the degranulation of mast cells exacerbate the vascular permeability. The fact that a quinazoline derivative suppresses the exacerbation of vascular permeability due to the intracutaneous administration of chymase shows that the quinazoline derivative suppresses inflammation involving mast cells caused by the chymase.

Evaluation Example 3: Test of Stability in Human Plasma

Human plasma was diluted two-fold with 50 mM sodium phosphate buffer (pH=7.2) for use as the test plasma solution. The test sample was made a DMSO solution of 1 mM concentration.

198  $\mu$ l of the above two-fold diluted plasma solution warmed to 37°C was added to 2  $\mu$ l of the test sample DMSO solution and the resultant mixture was stirred and incubated at 37°C. After 0, 5, and 15 minutes, 800  $\mu$ l of acetonitrile was mixed with the test sample-plasma mixture to remove the protein, then a centrifugation operation (12,000 rpm, 1 minute) was carried out and the supernatant obtained. This was diluted two-fold with distilled water and measured for of the test sample by HPLC analysis.

For the rate of recovery from the plasma, the rates of recovery at different times were calculated based on a calibration line of the test sample in a DMSO standard solution. The half-life ( $t_{1/2}$ ) in plasma was calculated by exponential recurrence analysis from the rates of recovery of these different times. The half-lives ( $t_{1/2}$ ) in plasma of representative compounds are shown in Table 1.

Preparation Example 1: Production of Tablets

100.0 g of Compound 1 was mixed with microcrystalline cellulose in an amount of 22.5 g and magnesium stearate in an amount of 2.5 g and then tabletized by a single-action type tabletizing machine to produce tablets each containing 200 mg of Compound 1 and

having a diameter of 9 mm and a weight of 250 mg.

Preparation Example 2: Production of Granules

30 g of Compound 1 was mixed well with lactose in an amount of 265 g and magnesium stearate in an amount of 5 g. The mixture was pressed molded, then pulverized and the granules sieved to obtain excellent 10% granules of 20 to 50 mesh.

Preparation Example 3: Production of Suppository

Vitepsol H-15 (made by Dynamite Nobel Co.) was warmed to melt. To this was added Compound 1 to a concentration of 12.5 mg/ml. This was homogeneously mixed, then was added in 2 ml amounts to a rectal suppository mold and cooled to obtain rectal suppositories each containing 25 mg of the Compound 1.


INDUSTRIAL APPLICABILITY

The quinazoline derivative of the present invention inhibits chymase and further suppresses the exacerbation of vascular permeability induced by chymase, and therefore, is useful as a medicament for the prevention or treatment of allergic diseases or rheumatic diseases or cardiac and circulatory system diseases arising due to the abnormal exacerbation of angiotensin II production. Examples of such diseases are inflammatory diseases for which mast cells are predicted as being closely related, for example, bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriosis, rheumatoid arthritis, cardiac and circulatory system diseases due to the abnormal exacerbation of Ang II production, for example, cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory disorders, revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including myocardial infarction, angioendothelia, or vascular disorders accompanying arterialization or atheroma.



CLAIMS

1. (Amended) A quinazoline derivative having the following formula (1) and a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group;

R<sup>1</sup> represents a hydroxyl group, an amino group, a C<sub>1</sub> to C<sub>4</sub> lower alkylamino group which may be substituted with a carboxylic acid group, a C<sub>7</sub> to C<sub>10</sub> lower aralkylamino group which may be substituted with a carboxylic acid group, an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, a C<sub>1</sub> to C<sub>4</sub> lower alkyl group substituted with a carboxylic acid group, or a C<sub>2</sub> to C<sub>4</sub> lower alkylene group which may be substituted with a carboxylic acid group;

R<sup>2</sup> and R<sup>3</sup> may be the same or different and represent a hydrogen atom, an unsubstituted or substituted C<sub>1</sub> to C<sub>4</sub> lower alkyl group, a halogen atom, a hydroxyl group, a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, an amino group, an unsubstituted or substituted C<sub>1</sub> to C<sub>4</sub> lower

09763213 041201

alkylamino group, an unsubstituted or substituted C<sub>7</sub> to C<sub>10</sub> aralkylamino group, an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, or a carboxylic acid group or

when the ring A is a benzene ring, R<sup>1</sup> and R<sup>2</sup> may form, together with the substituting benzene ring, a fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group and R<sup>3</sup> is the same as defined above; and

X represents a hydrogen atom, a C<sub>1</sub> to C<sub>4</sub> lower alkyl group, a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, a halogen atom, a hydroxyl group, an amino group, or a nitro group, with the proviso that, when the ring A is a benzene ring, R<sup>1</sup> is an amino group and both R<sup>2</sup> and R<sup>3</sup> are a hydrogen atom, R<sup>1</sup> is not positioned at the para-position to the sulfonyl group.

2. A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R<sup>1</sup> is a hydroxyl group, an amino group, a C<sub>1</sub> to C<sub>4</sub> lower alkylamino group substituted with a carboxylic acid group, or an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid substituted with a carboxylic acid group.

3. A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1 or 2, wherein,

0976323-041201

**ART 34 AMDT**

- 43/1 -

in the formula (1),  $R^2$  is a carboxylic acid group or a hydrogen atom.

4. A quinazoline derivative or a pharmaceutically

10240-0722460

acceptable salt thereof as claimed in any one of claims 1 to 3, wherein R<sup>3</sup> in the formula (I) is a hydrogen atom.

5. A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier therefor.

6. A chymase inhibitor having as an effective ingredient a quinazoline derivative or its pharmaceutically salt according to any one of claims 1 to 4.

7. A pharmaceutical composition as claimed in claim 5 for prevention or treatment of allergic diseases or rheumatic diseases.

8. A pharmaceutical composition as claimed in claim 5 for prevention or treatment of bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriosis, or rheumatoid arthritis.

9. A pharmaceutical composition as claimed in claim 5 for prevention or treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Angiotensin II production.

10. A pharmaceutical composition as claimed in claim 5 for prevention or treatment of cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory diseases, revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including cardiac infarction, angioendothelia, or vascular disorders accompanying arterialization and atheroma.

11. (Amended) A sulfonylurea derivative having the formula (4):

006341 04201  
10440 0229460


an amino group acylated with a C<sub>1</sub> to C<sub>4</sub> lower aliphatic acid which may be substituted with a carboxylic acid group, an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a C<sub>1</sub> to C<sub>4</sub> lower alkanesulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, or a carboxylic acid group or

when the ring A is a benzene ring, R<sup>1</sup> and R<sup>2</sup> may form, together with the substituting benzene ring, a fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group and R<sup>3</sup> is the same as defined above; and

X' is X, which may be protected with a protecting group and which represents a hydrogen atom, a C<sub>1</sub> to C<sub>4</sub> lower alkyl group, a C<sub>1</sub> to C<sub>4</sub> lower alkoxy group, a halogen atom, a hydroxyl group, an amino group, or a nitro group, with the proviso that, when the ring A is a benzene ring, R<sup>1</sup> is an amino group and both R<sup>2</sup> and R<sup>3</sup> are a hydrogen atom, R<sup>1</sup> is not positioned at the para-position to the sulfonyl group.

12. (Amended) A sulfonylurea derivative having the formula (7):

09763613-041201



wherein, the ring A represents an aryl group;

$R^{1'}$  is  $R^1$ , which may be protected with a protecting group and which represents a hydroxyl group,

093333 04404  
T02140 00000000

amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a carboxylic acid group, an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a carboxylic acid group, or a carboxylic acid group or

when the ring A is a benzene ring,  $R^1$  and  $R^2$  may form together with the substituting benzene ring a fused heterocyclic ring which may be substituted with a carboxylic acid and in which the carbon atom in the ring may form a carbonyl group and  $R^3$  is the same as defined above;

$R^4$  represents a protecting group for a carboxyl group; and

$X'$  is X, which may be protected with a protecting group and which represents a hydrogen atom, a  $C_1$  to  $C_4$  lower alkyl group, a  $C_1$  to  $C_4$  lower alkoxy group, a halogen atom, a hydroxyl group, an amino group, or a nitro group, with the proviso that, when the ring A is a benzene ring,  $R^1$  is an amino group and both  $R^2$  and  $R^3$  are a hydrogen atom,  $R^1$  is not positioned at the para-position to the sulfonyl group.

13. A method for producing a quinazoline derivative having the formula (1) according to claim 1 comprising:


allowing a sulfonylurea derivative having the formula (4) according to claim 11 to a ring-closing reaction with a condensation agent or

deprotecting a carboxyl group of the sulfonylurea derivative having the formula (7) according to claim 12, followed by effecting a ring-closing reaction with a condensation agent.

09763213 041201

ABSTRACT

A quinazoline derivative having the formula (1):



10 or a pharmaceutically acceptable salt thereof, which has  
a chymase inhibitory activity and suppresses the  
exacerbation of vascular permeability induced by chymase  
and useful as a medicament, and a pharmaceutical  
15 composition containing the same as an essential  
ingredient.

T0240-04100



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Declaration and Power of Attorney For Patent Application

### 特許出願宣言書及び委任状

### Japanese Language Declaration

### 日本語宣言書

下の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

QUINAZOLINE DERIVATIVES AND

PHARMACEUTICAL APPLICATIONS THEREOF

上記発明の明細書（下記の欄でx印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

☐ 月 日に提出され、米国出願番号または特許協定条約国際出願番号を \_\_\_\_\_ とし、  
（該当する場合） \_\_\_\_\_ に訂正されました。

☒ was filed on February 20, 2001  
as United States Application Number or  
PCT International Application Number  
PCT/JP99/04503 and was amended on  
August 25, 2000 (if applicable).  
Under PCT Art. 34.

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Japanese Language Declaration (日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国外の国の少なくとも一カ国を指定している特許協力条約365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

### Prior Foreign Application(s)

外国での先行出願

10-235633 (Pat. Appln.)

(Number)  
(番号)

Japan

(Country)  
(国名)

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

### Priority Not Claimed

優先権主張なし

21/August/1998

(Day/Month/Year Filed)  
(出願年月日)

☐

(Number)  
(番号)

(Country)  
(国名)

(Day/Month/Year Filed)  
(出願年月日)

☐

私は、第35編米国法典119条(e)項に基づいて下記の米国外の特許出願規定に記載された権利をここに主張いたします。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国外の特許出願に記載された権利、又は米国外を指定している特許協力条約365条(c)に基づき権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国外の特許出願に開示されていない限り、その先行米国外出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Status: Patented, Pending, Abandoned)  
(現況: 特許許可済、係属中、放棄済)

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

(Status: Patented, Pending, Abandoned)  
(現況: 特許許可済、係属中、放棄済)

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じることに基づき表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行えば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## Japanese Language Declaration

(日本語宣言書)

委任状： 私は下記の発明者として、本出願に関する一切の  
手続きを米特許商標局に対して遂行する弁理士または代理人  
として、下記の者を指名いたします。(弁理士、または代理  
人の氏名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint  
the following attorney(s) and/or agent(s) to prosecute this  
application and transact all business in the Patent and Trademark  
Office connected therewith (list name and registration number)

William L. Mathis	17,337	Robert G. Mukai	28,531	William H. Benz	25,952
Peter H. Smolka	15,913	George A. Hovanec, Jr.	28,223	Peter K. Skiff	31,917
Robert S. Swecker	19,885	James A. LaBarre	28,632	Richard J. McGrath	29,195
Platon N. Mandros	22,124	E. Joseph Gess	28,510	Matthew L. Schneider	32,814
Benton S. Duffett, Jr.	22,030	R. Danny Huntington	27,903	Michael G. Savage	32,596
Joseph R. Magnone	24,239	Eric H. Weisblatt	30,505	Gerald F. Swiss	30,113
Norman H. Stepno	22,716	James W. Peterson	26,057	Michael J. Ure	33,089
Ronald L. Grudziecki	24,970	Teresa Stanek Rea	30,427	Charles F. Wieland III	33,096
Frederick G. Michaud, Jr.	26,003	Robert E. Krebs	25,885	Bruce T. Wieder	33,815
Alan E. Kopecki	25,813	William C. Rowland	30,888	Todd R. Walters	34,040
Regis E. Slutter	26,999	T. Gene Dillahunt	25,423		
Samuel C. Miller, III	27,360	Patrick C. Keane	32,858		
Ralph L. Freeland, Jr.	16,110	Bruce J. Boggs, Jr.	32,344		

書類送付先

Send Correspondence to:

Ronald L. Grudziecki  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

直接電話連絡先: (名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

Ronald L. Grudziecki  
at (703) 836-6620

唯一または第一発明者名	Full name of sole or first inventor	
	<u>Harukazu Fukami</u>	
発明者の署名	Inventor's signature	Date
日付	<u>Harukazu Fukami</u>	<u>March 1, 2001</u>
住所	Residence	
	<u>Minami-ku, Kyoto, Japan</u>	<u>JPX</u>
国籍	Citizenship	
	<u>Japanese</u>	
私書箱	Post Office Address	
	<u>36, Shimadezaike-cho, Kisshoin,</u>	
	<u>Minami-ku, Kyoto 601-8373, Japan</u>	
第二共同発明者	Full name of second joint inventor, if any	
	<u>Akiko Ito</u>	
第二共同発明者	Second inventor's signature	Date
日付	<u>Akiko Ito</u>	<u>Mar. 1st '01</u>
住所	Residence	
	<u>Rockville, MD, United States of America</u>	
国籍	Citizenship	
	<u>Japanese</u>	<u>MD</u>
私書箱	Post Office Address	
	<u>261 Congressional Ln. #708,</u>	
	<u>Rockville, MD 20852</u>	
	<u>United States of America</u>	

(第三以降の共同発明者についても同様に記載し、署名をす  
ること)

(Supply similar information and signature for third and subsequent  
joint inventors.)

